Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm
Launched by SAFAA AA KHALED · Mar 16, 2020
Trial Information
Current as of September 07, 2025
Unknown status
Keywords
ClinConnect Summary
Classic Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including Chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) (Levine et al., 2007).
According to WHO 2016 classification which also included chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL), and MPN, unclassifiable, Out of the four classic types of MPNs, CML is positive for BCR-ABL1gene , while PV, ET, and PMF are negative for BCR-ABL1 gene (Thapa and Rogers, 2019).
CML is characterized by a balanced genetic transloc...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients diagnosed one of classic MPNs (CML, PV, ET, PMF).
- Exclusion Criteria:
- • Patients below 18 years.
- • Pregnancy.
- • Any associated Solid or hematopoietic neoplasm.
About Safaa Aa Khaled
Safaa A.A. Khaled is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on rigorous scientific methodology and ethical practices, the organization collaborates with healthcare professionals and research institutions to conduct high-quality clinical trials. Their expertise spans various therapeutic areas, ensuring a deep understanding of the complexities involved in drug development and patient care. Safaa A.A. Khaled is dedicated to fostering transparency and integrity in clinical research, ultimately contributing to the progression of healthcare advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
doha M ali, MD
Principal Investigator
Assiut University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials